Hong Jae Chon, Professor of Medical Oncology and Director of the Cancer Center at CHA Bundang Medical Center, shared on X:
“Expert perspectives on first-line nivolumab plus ipilimumab in unresectable HCC from Check Mate9 DW!
A 4-part podcast covering primary efficacy, key subgroups, the early OS crossing, and imAE management
- Nivo+Ipi vs Len/Sor (N = 668): median OS 23.7 vs 20.6 mo; ORR 36% vs 13%; 36-mo OS 38% vs 24%
- Nivo+Ipi showed consistent efficacy across ALBI grades & high-risk subgroups, with potential preservation of liver function
- Early OS curve crossing: HR 1.65 at 0–6 mo, then 0.61 after 6 mo. This was substantially driven by deaths from AEs unrelated to study treatment.
- imAEs occurred in 58% (Gr 3–4, 28%); high-dose steroid use did not appear to compromise efficacy DOI:
Title: First-line Management of Unresectable Hepatocellular Carcinoma: Clinical Perspectives from the CheckMate 9DW Study
Authors: Bruno Sangro, Peter Galle, David Tai, Thomas Yau
You can also read: Raising Awareness for Cholangiocarcinoma and Liver Cancers – Cholangiocarcinoma Foundation
